Therapeutic Antibodies DigiTAb
PLA submitted Aug. 6 for treatment of the effects of digoxin toxicity. If approved, DigiTAB will be a direct competitor to Glaxo Wellcome's Digibind and will be marketed in the U.S. by Altana
You may also be interested in...
Wyeth-Ayerst plans to manufacture the rheumatoid arthritis therapy Enbrel at a West Greenwich, R.I. biopharmaceutical facility purchased from Glaxo.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011